88 related articles for article (PubMed ID: 24097894)
1. False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125.
Prassas I; Brinc D; Farkona S; Leung F; Dimitromanolakis A; Chrystoja CC; Brand R; Kulasingam V; Blasutig IM; Diamandis EP
Clin Chem; 2014 Feb; 60(2):381-8. PubMed ID: 24097894
[TBL] [Abstract][Full Text] [Related]
2. CUB and zona pellucida-like domain-containing protein 1 (CUZD1): a novel serological biomarker for ovarian cancer.
Leung F; Soosaipillai A; Kulasingam V; Diamandis EP
Clin Biochem; 2012 Dec; 45(18):1543-6. PubMed ID: 22985796
[TBL] [Abstract][Full Text] [Related]
3. Generation of monoclonal antibodies and development of an immunofluorometric assay for the detection of CUZD1 in tissues and biological fluids.
Farkona S; Soosaipillai A; Filippou P; Korbakis D; Serra S; Rückert F; Diamandis EP; Blasutig IM
Clin Biochem; 2017 Dec; 50(18):1168-1174. PubMed ID: 28746862
[TBL] [Abstract][Full Text] [Related]
4. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
5. Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases.
Farkona S; Soosaipillai A; Filippou P; Liaskos C; Bogdanos DP; Diamandis EP; Blasutig IM
Clin Chem Lab Med; 2017 Aug; 55(10):1574-1581. PubMed ID: 28343172
[TBL] [Abstract][Full Text] [Related]
6. CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases.
Liaskos C; Rigopoulou EI; Orfanidou T; Bogdanos DP; Papandreou CN
Clin Dev Immunol; 2013; 2013():968041. PubMed ID: 23710207
[TBL] [Abstract][Full Text] [Related]
7. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].
Papp M; Sipeki N; Tornai T; Altorjay I; Norman GL; Shums Z; Roggenbuck D; Fechner K; Stöcker W; Antal-Szalmas P; Veres G; Lakatos PL
J Crohns Colitis; 2015 Aug; 9(8):659-68. PubMed ID: 25968583
[TBL] [Abstract][Full Text] [Related]
8. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.
Lee MJ; Na K; Jeong SK; Lim JS; Kim SA; Lee MJ; Song SY; Kim H; Hancock WS; Paik YK
J Proteome Res; 2014 Nov; 13(11):4878-88. PubMed ID: 25057901
[TBL] [Abstract][Full Text] [Related]
9. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
Shi HJ; Jin C; Fu DL
World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease.
Michaels MA; Jendrek ST; Korf T; Nitzsche T; Teegen B; Komorowski L; Derer S; Schröder T; Baer F; Lehnert H; Büning J; Fellerman K; Sina C
Inflamm Bowel Dis; 2015 Dec; 21(12):2864-72. PubMed ID: 26273818
[TBL] [Abstract][Full Text] [Related]
12. Quantification of 15-F2t-isoprostane in human plasma and urine: results from enzyme-linked immunoassay and liquid chromatography/tandem mass spectrometry cannot be compared.
Klawitter J; Haschke M; Shokati T; Klawitter J; Christians U
Rapid Commun Mass Spectrom; 2011 Feb; 25(4):463-8. PubMed ID: 21259353
[TBL] [Abstract][Full Text] [Related]
13. CUZD1 is a critical mediator of the JAK/STAT5 signaling pathway that controls mammary gland development during pregnancy.
Mapes J; Li Q; Kannan A; Anandan L; Laws M; Lydon JP; Bagchi IC; Bagchi MK
PLoS Genet; 2017 Mar; 13(3):e1006654. PubMed ID: 28278176
[TBL] [Abstract][Full Text] [Related]
14. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC).
Liu L; Xiang J; Chen R; Fu D; Hong D; Hao J; Li Y; Li J; Li S; Mou Y; Mai G; Ni Q; Peng L; Qin R; Qian H; Shao C; Sun B; Sun Y; Tao M; Tian B; Wang H; Wang J; Wang L; Wang W; Wang W; Zhang J; Zhao G; Zhou J; Yu X;
Int J Oncol; 2016 Mar; 48(3):900-7. PubMed ID: 26718269
[TBL] [Abstract][Full Text] [Related]
15. The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma.
Zhuge X; Guo C; Chen Y; Feng L; Jia R; Zhao Y; Sun K; Wang Z; Chen X
Pancreas; 2018; 47(10):1290-1295. PubMed ID: 30308534
[TBL] [Abstract][Full Text] [Related]
16. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
[TBL] [Abstract][Full Text] [Related]
17. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
[TBL] [Abstract][Full Text] [Related]
18. Variants in the pancreatic CUB and zona pellucida-like domains 1 (CUZD1) gene in early-onset chronic pancreatitis - A possible new susceptibility gene.
Rygiel AM; Unger LS; Sörgel FL; Masson E; Matsumoto R; Ewers M; Chen JM; Bugert P; Buscail L; Gambin T; Oracz G; Winiewska-Szajewska M; Mianowska A; Poznanski J; Kosińska J; Stawinski P; Płoski R; Koziel D; Gluszek S; Laumen H; Lindgren F; Löhr JM; Orekhova A; Rebours V; Rosendahl J; Párniczky A; Hegyi P; Sasaki A; Kataoka F; Tanaka Y; Hamada S; Sahin-Tóth M; Hegyi E; Férec C; Masamune A; Witt H
Pancreatology; 2022 Jun; 22(5):564-571. PubMed ID: 35589511
[TBL] [Abstract][Full Text] [Related]
19. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease.
Nazmeen A; Maiti S; Mandal K; Roy SK; Ghosh TK; Sinha NK; Mandal K
Med Chem; 2017; 13(8):796-804. PubMed ID: 28440189
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma.
Yang Z; Senninger N; Flammang I; Ye Q; Dhayat SA
J Cancer Res Clin Oncol; 2019 May; 145(5):1165-1178. PubMed ID: 30778748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
